Sapheon, Inc. Announces One Year First-In-Man Data; Enrollment Commences in European Post Market Study
Published: Jan 19, 2012
SANTA ROSA, Calif.--(BUSINESS WIRE)--Sapheon Inc. announced one year results in its first in-man safety trial of the Sapheon Closure System. At the one year mark, 100% of the great saphenous vein segments treated with the company’s novel proprietary vein sealant remained completely closed by ultrasound criteria. All patients reported significant improvement in symptoms compared to baseline. No device or procedure related serious adverse events occurred at any interval over the follow-up period.